Background: There are limited data on whether HIV-infected children in resource-limited countries who are receiving antiretroviral therapy (ART) are able to produce sustained, protective levels of measles antibody after multiple measles vaccinations. Methods: We administered an additional measles vaccine to HIV-infected children 15 months to 12 years of age receiving ART in Nairobi, Kenya. Measles antibody concentrations were determined by enzyme-linked immunosorbent assay at enrollment, 1 month, 12 months and 24 months post revaccination. Results: At enrollment, 125 (54%) of 232 study participants had protective concentrations of measles antibody. Measles seropositivity increased to 98% of all children at 1 month post revaccination but decreased to 71% at 12 months and 60% at 24 months post revaccination. Measles seroconversion and sustained measles seropositivity among those who were measles seronegative at enrollment was 25% at 24 months post revaccination. In this group, 39% of children with <50 copies/mL plasma HIV RNA measles seroconverted compared to 4% of children with plasma HIV RNA ≥1000 copies/mL (P = 0.018). Conclusions: Measles revaccination can result in a sustained antibody response in a subset of HIV-infected children receiving ART, especially among those with HIV suppression.
D
espite advances in reducing overall measles incidence in Africa, 1 several large and deadly measles outbreaks have occurred in countries with high adult and child HIV prevalence. 2 HIV infection reduces both initial and sustained immune responses to measles vaccination. A single measles vaccine at 9 months of age confers immediate protection to 25%-88% HIV-infected infants, [3] [4] [5] substantially lower than 85%-95% response rates among HIVuninfected infants. [6] [7] [8] Further, even in HIV-infected infants with an adequate initial response, fewer than 50% maintain protective antibody levels after 1 year. 4, 5 Vaccination after initiation of antiretroviral therapy (ART) may improve the response; however, many HIV-infected infants are not diagnosed and treated before receiving routine measles vaccination. 9 In areas with high incidence of both HIV and measles, the World Health Organization (WHO) suggests that the first measles vaccine may be offered as early as 6 months of age, followed by 2 additional doses according to the national immunization schedule. 10, 11 However, the scope and frequency of early routine immunization and supplementary immunization activities (SIA) SIA vary by country, and many countries have yet to implement these recommendations. 11 In October 2015, the WHO Strategic Advisory Group of Experts recommended an additional dose of measles-containing vaccine for HIV-infected children receiving highly active ART after immune reconstitution, but stated that further research is needed to monitor the long-term immune responses to measles vaccination in HIV-infected children revaccinated after starting ART. 12 We administered an additional measles vaccine to HIVinfected children on ART in Nairobi, Kenya, and determined the prevalence of measles seropositivity after 1, 12 and 24 months. Additionally, we explored factors associated with measles seroconversion at 24 months post revaccination among the HIV-infected children who were measles seronegative at enrollment.
MATERIALS AND METHODS

Study Participants and Procedures
HIV-infected children and their caregivers were recruited from the HIV Comprehensive Care Center at Kenyatta National Hospital in Nairobi, Kenya, during routine HIV care visits between May 2011 and January 2013, as previously described. 13 Caregivers willing to be screened were asked to read and sign an informed consent document, approved by Kenyatta National Hospital and the University of Washington. Children above 7 years of age were asked to assent to participation. Those eligible who chose not to enroll were given access to measles vaccination at no cost.
Eligibility criteria included age between 15 months and 12 years, HIV infection confirmed by HIV-1/2 enzyme-linked immunosorbent assay (ELISA) and/or polymerase chain reaction, on ART at the time of enrollment and CD4% ≥15. Child exclusion criteria included a history of adverse reaction to measles vaccination, allergy to gelatin or neomycin, hospitalization within the preceding 2 weeks, blood or plasma transfusion or receipt of immune globulin within last 6 months.
At enrollment, demographic and medical histories were collected from caregivers and immunization and treatment information
Laboratory Assays
Serum measles immunoglobulin G (IgG) was determined at enrollment, 1, 12 and 24 months post revaccination. CD4% was determined at enrollment, 6, 12 and 24 months post revaccination in accordance to standard monitoring practice. Plasma HIV RNA was determined at enrollment, 12 and 24 months post revaccination. Serum measles IgG antibodies were measured using an ELISA (Enzygnost; Siemens, Marburg, Germany). Optical density values were determined, and values >0.1 optical density were converted into measlesspecific IgG mIU/mL using manufacturer's calculations based on the First International WHO Reference Preparation Standards.
CD4% was determined by the University of Nairobi Paediatrics Laboratory, Kenya (FACSCalibur; BD Biosciences, San Jose, CA). To determine plasma HIV RNA, samples were stored at −80°C on site, and frozen samples were shipped to the University of Washington, Seattle, WA. Plasma HIV RNA levels were measured by the GenProbe HIV-1 RNA assay (Gen-Probe, San Diego, CA), which has been validated on the HIV subtypes prevalent in Kenya.
14 An exploratory analysis of cytomegalovirus (CMV) DNA quantification in plasma was performed, based on previous studies that suggest that CMV infection was associated with impaired responses to vaccination. 15 CMV was determined at baseline in a subset of participants at the University of Washington by real-time polymerase chain reaction. 16 Vitamin A levels were determined by measuring retinolbinding protein (RBP), C-reactive protein (CRP) and α-1-acidglycoprotein (AGP) using a sandwich ELISA technique. 17 Final determination of RBP concentration was adjusted in cases where CRP and AGP, markers for inflammation, were elevated.
18,19
Statistical Analyses
We defined response to measles revaccination in 2 ways: measles seropositivity (a measles IgG titer ≥200 mIU/mL at any time point) and measles seroconversion [an increase in measles IgG antibody titer from seronegative (measles IgG titer <200 mIU/mL) to seropositive levels at 1, 12 or 24 months post revaccination]. 20 We categorized plasma HIV RNA as <50, 50-999 and ≥1000 copies/mL based on the WHO definition of virologic failure in children. 21 Underweight (defined as a weight-for-age Z score < −2), wasted (defined as a weight-for-length/height Z score < −2) and stunted (defined as a length/height-for-age Z score < −2) were calculated using child growth standards developed by the WHO (WHO Anthro macroversion 3.2.2, Department of Nutrition, World Health Organization, Geneva, Switzerland). 22 Severe vitamin A deficiency was defined as an adjusted RBP concentration of <0.7 µmol/L and moderate deficiency as an adjusted RBP concentration of 0.7-1.05 µmol/L
.
To determine whether early vaccine response predicted durability, we assessed whether those who were measles seropositive at 24 months post revaccination had similar or higher antibody titers at 1 and 12 months post revaccination. Seronegative antibody levels were assigned a random number between 0 and 2.30 on the log 10 scale for these comparisons. To determine whether revaccination resulted in an increased proportion of those measles seropositive at 24 months post revaccination, we estimated the risk of measles seropositivity at 24 months by log-binomial regression with robust error variance. The potential association of baseline characteristics and measles seropositivity at 24 months was evaluated in univariate log-binomial regression models with robust error variance. Characteristics that were statistically significantly associated with measles seropositivity at 24 months post revaccination were included in a multivariate model. Baseline characteristics assessed included age, sex, measles serostatus at enrollment, CD4%, plasma HIV RNA, time on ART, WHO stage, vitamin A deficiency, length/heightfor-age Z score and stunting. Biologic plausibility and graphical techniques were used to find biologically relevant cutoffs for continuous correlates. Among 156 participants who were assessed for baseline CMV viremia, Pearson χ 2 was used to test differences in active CMV infection by measles serostatus at 24 months.
Maintenance of measles seropositivity after revaccination may involve a different immunologic mechanism than measles seroconversion; 23 thus, a separate analysis was performed to explore factors associated with seroconversion. We assessed the risk of measles seroconversion at 24 months post revaccination by log-binomial regression with robust error variance. The same baseline characteristics as mentioned above were evaluated for an association with measles seroconversion at 24 months post revaccination in both univariate and multivariate models. Analysis was performed using Stata (StataCorp. 2009, Stata Statistical Software: Release 11; StataCorp LP, College Station, TX).
RESULTS
Cohort Description
Of 272 children screened, 232 were enrolled and revaccinated. Cohort and caregiver characteristics and measles serostatus before revaccination were previously described. 13 Of the enrolled children, 220 (95%) attended their 1-month post revaccination visit, 224 (97%) attended their 12-month visit and 220 (95%) attended their 24-month visit.
Of 232 enrolled children, 228 (98%) had received at least 1 measles vaccine before 1 year of age. Boys comprised 53% of the cohort; median age was 7.5 years [interquartile range (IQR): 5.5-9.5 years] and median CD4% was 32 (IQR: 27-38). Of 216 (93%) children with recorded date of ART initiation, median time on ART was 3.4 years (IQR: 1.8-4.9). At enrollment, 148 (70%) children were recorded as having advanced stages of HIV (WHO stage III or IV). Though all children were on ART, only 40% had undetectable levels of HIV RNA <50 copies/mL, and 23% had plasma HIV RNA ≥1000 copies/mL. Fifty-nine (26%) of 229 children had low serum vitamin A levels: 52 (23%) with moderate deficiency and 7 (3%) with severe deficiency. Correction of RBP by CRP and AGP did not affect vitamin A deficiency classification. As measured by a length/height-forage Z score < −2, 54 (23%) children were stunted (Table 1) .
Measles Serostatus at 1, 12 and 24 Months Post Revaccination
Before revaccination, 125 (54%) of 232 participants were measles seropositive. This is higher than what was previously reported (48%) because of an updated classification of seropositivity and increased ELISA assay sensitivity.
13 CD4% was a correlate of seropositivity at enrollment: 49% of participants with a CD4% ≥25 had seropositive measles antibody titers compared with 30% of participants with a CD4% <25 [risk ratio (RR): 2.11; 95% confidence interval (CI): 1.04-2.70; P = 0.035]. 13 Fifty-nine percent of children with a plasma HIV RNA <50 copies/mL were measles seropositive at enrollment, compared with 49% with plasma HIV RNA 50-99 copies/mL (P = 0.36) and 44% with plasma HIV RNA ≥1000 copies/mL (P = 0.09).
Among the entire cohort at 1 month post revaccination, 216 (98%) of 220 children were measles seropositive. This proportion decreased to 158 (71%) of 224 at 12 months post revaccination and 132 (60%) of 220 at 24 months post revaccination (Fig. 1) . Two participants reported additional measles vaccinations through supplementary immunization activities, and both were measles seropositive at all timepoints.
Among the 125 children who were measles seropositive at enrollment, all remained seropositive at 1 month post revaccination. By 12 months post revaccination, 117 (98%) of 120 maintained their measles seropositivity, decreasing slightly to 107 (91%) of 118 by 24 months (Fig. 1 ). Eleven participants who were measles seropositive at enrollment reverted by 24 months: 9 had measlesspecific IgG antibody titers close to the seropositive threshold at all timepoints, and 2 participants had antibody titers well above the threshold at enrollment, with CD4% at or above 30 and <50 copies/ mL plasma HIV RNA at all timepoints.
Among the 107 children who were measles seronegative at enrollment, 98 (94%) of 102 seroconverted at 1 month post revaccination. Among 4 children who failed to seroconvert, 3 had plasma HIV RNA levels between 4417 and 693,650 copies/mL. Forty-one (39%) of 104 sustained measles seropositivity at 12 months, and 26 (25%) of 102 sustained seropositivity at 24 months post revaccination (Fig. 1) . In participants who were measles seropositive at 24 months post revaccination, early responses to revaccination were better, as measured by mean measles log 10 IgG titer. At 1 month post revaccination, mean log 10 IgG was 3.24 in those measles seropositive at 24 months compared with a mean log 10 IgG of 2.85 among those who were seronegative at 24 months (P = 0.001). At 12 months, those who were measles seropositive at 24 months also had higher levels than those who were measles seronegative at 24 months (mean log 10 IgG = 2.53 vs. log 10 IgG = 1.45, respectively; P < 0.001) (Fig. 2) .
Baseline Factors Associated With Measles Seropositivity at 24 Months Post Revaccination
In univariate models, children who were measles seropositive at enrollment were 3.6 times as likely to remain measles seropositive at 24 months post revaccination compared with those who were measles seronegative at time of revaccination (RR: 3.56; 95% CI: 2.54 -4.99; P < 0.001). Children with a CD4% ≥30 at enrollment were more likely to remain seropositive compared with those with a CD4% <30 (RR: 1.43; 95% CI: 1.10-1.85; P = 0.007). Children with a plasma HIV RNA ≥1000 copies/mL at time of revaccination were less likely to be measles seropositive compared with those with <50 copies/mL plasma HIV (RR: 0.56; 95% CI: 0.39-0.82; P = 0.002). There were no statistically significant associations between baseline age, sex, time on ART, WHO stage, nutritional status or vitamin A status and measles seropositivity at 24 months post revaccination (Table 2 ). In multivariate analyses, both measles serostatus at baseline [adjusted RR (aRR): 3.43; 95% CI: 2.45-4.8; P < 0.001] and plasma HIV RNA (aRR: 0.67; 95% CI: 0.51-0.87; P = 0.003) remained significantly associated with measles seropositivity at 24 months. A second multivariate model that included CD4% and measles serostatus at baseline was run because of collinearity between plasma HIV RNA and CD4%. CD4% was not significantly associated with measles seropositivity at 24 months after adjusting for measles serostatus at baseline (P = 0.77) ( Table 3) .
Twenty-eight (18%) of 156 children had detectable CMV viremia at baseline. Of the 74 who were measles seropositive at 24 months, 11 (15%) had CMV viremia, compared with 17 (20%) of 82 who were measles seronegative at 24 months (P = 0.34).
Factors Predictive of Measles Seroconversion at 24 Months Post Revaccination
We investigated factors that were associated with measles seroconversion at 24 months post revaccination among those who were measles seronegative at baseline. In univariate models, children with plasma HIV RNA ≥1000 copies/mL were 90% less likely to seroconvert and maintain measles antibody seropositivity compared with children who had plasma HIV RNA <50 copies/ mL (RR: 0.09; 95% CI: 0.01-0.65; P = 0.017). Thirty-nine percent of children with <50 copies/mL plasma HIV RNA at enrollment seroconverted at 24 months post revaccination, compared with 17% of children with plasma HIV RNA 50-999 copies/mL and 4% of children with a plasma HIV RNA ≥1000 copies/mL (Table 4) .
In univariate models, there was a trend toward larger length/ height-for-age Z score at enrollment being associated with measles seroconversion at 24 months post revaccination (RR: 1.29; 95% CI: 0.99-1.68; P = 0.063). Neither CD4% nor moderate vitamin A deficiency was significantly associated with measles seroconversion at 24 months, but of the 4 participants who had vitamin A deficiency, none seroconverted at 24 months. Stunting, WHO stage, time on ART, age and sex were not statistically significantly associated with measles seroconversion (Table 4) .
A multivariate model that included CD4% and length/ height-for-age Z score resulted in risk estimates similar to univariate analyses; CD4% stayed moderately significant (P = 0.060), while length/height-for-age Z score was statistically significant (P = 0.036). A second multivariate model that included plasma HIV RNA and length/height-for-age Z score was run because of collinearity between plasma HIV RNA and CD4%. Plasma HIV RNA <50 copies/mL remained significantly associated with measles seroconversion at 24 months when compared with plasma HIV RNA ≥1000 copies/mL (aRR: 0.09; 95% CI: 0.01-0.67; P = 0.018), and length/height-for-age Z score was not significantly associated with measles seroconversion at 24 months (P = 0.11) ( Table 5) .
DISCUSSION
In this prospective study of the immunogenicity of measles revaccination in HIV-infected Kenyan children on ART, we found that 54% of children were measles antibody seropositive before revaccination, 71% of children were measles seropositive at 12 months and 60% of children were measles seropositive at 24 months after revaccination. This is the largest study to describe the long-term immunogenicity of measles revaccination in HIVinfected children on ART in sub-Saharan Africa.
Children in this Kenyan cohort did not respond to measles revaccination and other reported cohorts. A study in the United States found that approximately half of HIV-infected children lacked protective levels of measles antibody despite more than 80% coverage with 2 doses of the measles, mumps and rubella vaccine. 24 Two months after revaccination, seropositivity increased to 89% and remained at 80% 1.5 years post revaccination. 24 In Thailand, Aurpibul et al [25] [26] [27] found that 42% of HIV-infected children on ART had protective levels of measles antibody, which increased to 90% 1 month after revaccination and fell to 85% by 3 years after revaccination. One reason for the differences may be HIV suppression, as 97% of children in the Thailand cohort were HIV suppressed. 25 In the US cohort, approximately 60% of children had low or <50 copies/mL levels of HIV suppression, which is similar to this Kenyan cohort. Eight participants who have measles serostatus data at 24 months are not included in this figure because of missing data from 1 month. These participants missed the month 1 visit but returned at the 24-month visit. At both enrollment and 24 months, 3 were measles seronegative and 5 were measles seropositive. Measles seropositivity at time of revaccination was the strongest predictor of measles seropositivity at 24 months post revaccination, though plasma HIV RNA was also associated with maintaining measles seropositivity or seroconverting. Among those who were measles seronegative at enrollment, plasma HIV RNA was a significant predictor of measles seroconversion at 24 months post revaccination, even in multivariate models. HIV infection affects the quantity and quality of antibody response to measles vaccination, [28] [29] [30] and initiation of ART after measles vaccination is not sufficient to restore measles antibody response. 3 As in our study, other studies of measles revaccination in HIV-infected children on ART found that the response was related more to suppressed HIV replication than to CD4%. 24, 31 This suggests that the ability to sustain an immune response to measles vaccination may be hindered by high levels of HIV replication, which is associated with turnover and depletion of B and T cells needed for memory. 23 Results from this study may inform policy aimed at reducing measles transmission. Measles is targeted for elimination in 5 WHO regions by 2020. 32 A challenge to this goal is the infectious nature of measles, as it requires 95% of population immunity to interrupt transmission. 33 The current WHO Strategic Advisory Group of Experts guidelines recommend an additional dose of measles-containing vaccine for HIV-infected children receiving ART after immune reconstitution. This study suggests that plasma HIV RNA measurement may be more indicative of immune reconstitution for the purpose of measles revaccination than CD4% measurement. In settings where measurement of plasma HIV RNA is not available, measurement of immune reconstitution when CD4 reaches 20%-25%, or 6-12 months after initiation of ART if CD4 monitoring is not available, as recommended by the WHO, is appropriate. 12 Special attention to immunization in children with HIV may be necessary to reach elimination goals. The current measles immunization policy for HIVinfected infants in Kenya is to provide 2 routine vaccines at 6 and 9 months of age. This policy may be increasingly implemented as early infant HIV diagnosis is scaled up; however, it does not impact the more than 100,000 estimated children already living with HIV in Kenya. 34 Between 2005 and 2015, 5 SIA campaigns were conducted with response to measles outbreaks, 35 typically focusing on children under 5. Our study demonstrates that a susceptible population of older HIV-infected children may not be targeted by SIA campaigns. As such, measles vaccination campaigns could be facilitated through HIV care clinics, especially during measles outbreaks. HIV-infected children on ART attend clinic every few months to receive a prescription refill and for disease monitoring, so a clinic-based delivery system could directly access this susceptible group in a manner that minimizes additional human and physical resources.
While this study had excellent follow-up and retention, there were several limitations. We used ELISA to determine protection against clinical measles, and the gold standard for determining protection against measles is a plaque reduction neutralization technique. ELISA results are closely associated with plaque reduction neutralization, though they lack sensitivity to detect low levels of measles antibody. 36 However, the smallest antibody concentration detectable using our ELISA is approximately 200 mIU/mL, which is a higher titer than what is considered minimally protective against clinical measles. 20 Because we are not measuring cellular response to measles infection, we cannot assume lack of clinical protection in those with antibody levels below this threshold, though a study done in a subset of this cohort suggests that durable antibody response may correspond to lower T cell activation and anergy. 37 Another limitation is the use of RBP as a surrogate for vitamin A; however, RBP is a sensitive and specific surrogate measure of plasma retinol, 17, 38 even in HIV-infected individuals, 39 and is often used as a reliable surrogate.
Because we revaccinated all children, we cannot compare how many children who were measles seropositive at time of revaccination would have remained measles seropositive in the absence of revaccination. Annual measles cases in Kenya during the study ranged from 190 in 2013 to 2395 in 2011. 40 No children displayed clinical characteristics of measles infection during study follow-up, and the study was designed to mimic the potential benefit of measles revaccination in a population of HIV-infected children who do not undergo routine measles antibody titers.
In conclusion, this study provides evidence that measles revaccination may result in a sustained antibody response in a subset of HIV-infected children, and reinforces the importance of HIV suppression to achieve maximum immunogenicity of measles revaccination. Measles revaccination in HIV-infected children on ART with suppressed HIV replication may improve population wide protective levels of measles antibody in areas of high HIV prevalence.
Rheumatic heart disease is a sequela of acute rheumatic fever, which is usually a disease of poverty associated with overcrowding, poor sanitation and other social determinants of poor health. The near elimination of acute rheumatic fever and reduction in the rates of rheumatic heart disease in high-income countries during the late 20th century was attributed in part to improvements in socioeconomic conditions and the widespread use of penicillin G benzathine to treat streptococcal pharyngitis. The remaining burden of rheumatic heart disease is found mostly in low-income and middle-income countries and among immigrants and older adults in high-income countries.
The World Health Organization and World Heart Federation have called for a 25% reduction in mortality due to cardiovascular causes, including rheumatic heart disease, by the year 2025. As part of the 2015 Global Burden of Diseases study, the global, regional and national burden of rheumatic heart disease was estimated for the years 1990 through 2015.
Two Global Burden of Disease analytic tools, the Cause of Death Ensemble model and DisMod-MR 2.1, were used to produce estimates of mortality and prevalence, including estimates of uncertainty. Countries were considered to have 1 of 2 patterns of rheumatic heart disease: endemic, with high mortality and prevalence among children, and nonendemic, with low mortality and prevalence among children and predominance at older ages, when the delayed sequelae of rheumatic heart disease occur. To make predictions for all countries, estimates were made in an analytical cascade from the world to 7 super-regions, then to 21 world regions and then to 195 countries and territories.
On the basis of results derived from the ensemble models, it was estimated that there were 347,500 deaths (95% uncertainty interval: 328,300-367,100) from rheumatic heart disease in 1990 and 319,400 deaths (95% uncertainty interval: 297,300-337,300) in 2015, a decrease of 8.1% (95% uncertainty level: 2.7-13.5). Global age-standardized mortality from rheumatic heart disease decreased from 9.2 deaths per 100,000 population (95% uncertainty interval: 8.7-9.7) in 1990 to 4.8 deaths per 100,000 population (95% uncertainty interval: 4.4-5.1) in 2015, a decrease of 47.8% (95% uncertainty interval: 44.7-50.9). An estimated 77% and 82% of the deaths in 1990 and 2015, respectively, occurred in locations with an endemic disease pattern.
Patterns of mortality due to rheumatic heart disease varied significantly according to world region in 2015. The largest number of deaths occurred in East Asia and South Asia. The highest age-standardized death rates occurred in Oceania, South Asia and central sub-Saharan Africa, the only regions where the 95% uncertainty intervals in 1990 and 2015 overlap. In 2015, the countries with the highest estimated numbers of deaths due to rheumatic heart disease were India (119,100 deaths), China (72,600) and Pakistan (18, 900) .
The estimated age-standardized prevalence of rheumatic heart disease in 2015 was 444 cases per 100,000 population for countries with an endemic pattern and 3.4 cases per 100,000 population for countries with a nonendemic pattern. In 2015, the age-standardized prevalence remained highest in Oceania, followed by central sub-Saharan Africa and South Asia. In 2015, the countries with the largest estimated numbers of cases of rheumatic heart disease were India (13.17 million cases), China (7.07 million), Pakistan (2.25 million), Indonesia (1.18 million) and the Democratic Republic of the Congo (805,000), together accounting for 73% of global cases.
Comment: The Global Burden of Disease data are a timely reminder to the global community that rheumatic heart disease is far from being conquered (Marijon E, Celermajer DS, Jouven X. N Engl J Med. 2017;377: 780-781). The marked global heterogeneity of the burden of rheumatic heart disease, with near-zero prevalence in developed countries, contrasts sharply with substantial prevalence and mortality in developing areas.
The goal should be global eradication of rheumatic heart disease. Improved living conditions, public education, universal access to early antibiotic therapy for streptococcal sore throat and widespread screening for early valvular disease should be cornerstones of eradication efforts. A better understanding of the immunogenic determinants of the disease may provide a potential route to identify relevant bacterial antigens that could be used in the development of a vaccine against group A streptococcus. Genomewide association studies may aid in the identification of vulnerable persons, allowing for targeted therapies.
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